Pages that link to "Item:Q2893418"

The following pages link to Continual Reassessment Method for Partial Ordering (Q2893418):

Displaying 17 items.

• A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate (Q1733138) (← links)
• A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering (Q2170396) (← links)
• Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity (Q2441853) (← links)
• Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
• Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations (Q5041342) (← links)
• Flexible use of copula‐type model for dose‐finding in drug combination clinical trials (Q6055718) (← links)
• Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information (Q6085905) (← links)
• A simulation-free approach to assessing the performance of the continual reassessment method (Q6617412) (← links)
• CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome (Q6625779) (← links)
• A nonparametric Bayesian method for dose finding in drug combinations cancer trials (Q6626759) (← links)
• Improving safety of the continual reassessment method via a modified allocation rule (Q6627502) (← links)
• Consistency of the when the curve is not monotone and its application to the POCRM (Q6627746) (← links)
• Early completion of phase I cancer clinical trials with Bayesian optimal interval design (Q6628100) (← links)
• Practical implementation of the partial ordering continual reassessment method in a phase I combination-schedule dose-finding trial (Q6629425) (← links)
• Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer (Q6636217) (← links)
• Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials (Q6637076) (← links)
• Dual-agent dose-finding in phase I clinical trial -- an extension of rapid enrollment design (Q6652600) (← links)